A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2009.07.005PMID 19698899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum.

  2009cited by this paper
• Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study

  2009cited by this paper
• Area-level socioeconomic status in relation to outcomes in γ-hydroxybutyrate intoxication

  2009cited by this paper
• Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse.

  2008cited by this paper
• Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.

  2008cited by this paper
• Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.

  2008cited by this paper
• Patterns and incidence of γ‐hydroxybutyrate (GHB)‐related ambulance attendances in Melbourne, Victoria

  2008cited by this paper
• High mortality rates among GHB abusers in Western Sweden

  2008cited by this paper
• Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB).

  2008cited by this paper
• The epidemiology of GHB and ketamine use in an Australian household survey.

  2008cited by this paper
• Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats.

  2008cited by this paper
• Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.

  2008cited by this paper
• Gamma-hydroxybutyric acid in male and female cynomolgus monkeys trained to discriminate 1.0 or 2.0 g/kg ethanol

  2008cited by this paper
• Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

  2008cited by this paper
• The Involvement of Drugs and Alcohol in Drug-Facilitated Sexual Assault

  2008cited by this paper
• Gamma Hydroxybutyrate: An Ethnographic Study of Recreational Use and Abuse

  2008cited by this paper
• Intoxications due to Ingestion of γ-Butyrolactone: Organ Distribution of γ-Hydroxybutyric Acid and γ-Butyrolactone

  2008cited by this paper
• Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases.

  2007cited by this paper
• Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD).

  2007cited by this paper
• Modification of ethanol’s reinforcing effectiveness in rhesus monkeys by cocaine, flunitrazepam, or gamma-hydroxybutyrate

  2007cited by this paper
• High-Risk Behaviors and Hospitalizations Among Gamma Hydroxybutyrate (GHB) Users

  2007cited by this paper
• Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: A case series

  2007cited by this paper
• Relative Abuse Liability of γ-Hydroxybutyric Acid, Flunitrazepam, and Ethanol in Club Drug Users

  2007cited by this paper
• Disposition of Gamma-Hydroxybutyric Acid in Conventional and Nonconventional Biologic Fluids After Single Drug Administration: Issues in Methodology and Drug Monitoring

  2007cited by this paper
• Schizophrenia and co-occurring substance use disorder.

  2007cited by this paper
• Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

  2007cited by this paper
• EFNS guidelines on management of narcolepsy

  2006cited by this paper
• Relative Abuse Liability of GHB in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects of Supratherapeutic Doses of Triazolam, Pentobarbital, and GHB

  2006cited by this paper
• Gamma-hydroxybutyrate and Ethanol Effects and Interactions in Humans

  2006cited by this paper
• GHB use among gay and bisexual men.

  2006cited by this paper
• The clinical development of gamma-hydroxybutyrate (GHB).

  2006cited by this paper
• Problems with latest Xyrem group investigation.

  2006cited by this paper
• A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB).

  2006cited by this paper
• Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003.

  2006cited by this paper
• Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use.

  2006cited by this paper
• Trends in γ-Hydroxybutyrate (GHB) and Related Drug Intoxication: 1999 to 2003

  2006cited by this paper
• The Clinical Development of γ-Hydroxybutyrate (GHB)

  2006cited by this paper
• Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.

  2005cited by this paper
• Patterns of Simultaneous Polysubstance Use in Canadian Rave Attendees

  2005cited by this paper
• A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.

  2005cited by this paper
• Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period.

  2005cited by this paper
• Gamma hydroxy butyrate abuse and dependency

  2005cited by this paper
• Narcolepsy and disorders of excessive somnolence.

  2005cited by this paper
• A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy.

  2004cited by this paper
• Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia.

  2004cited by this paper
• Fatalities associated with the use of γ‐hydroxybutyrate and its analogues in Australasia

  2004cited by this paper
• Forensic cases involving the use of GHB in The Netherlands.

  2003cited by this paper
• Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and γ-butyrolactone in rhesus monkeys

  2003cited by this paper
• The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia.

  2003cited by this paper
• The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms

  2003cited by this paper
• Principles of initial experimental drug abuse liability assessment in humans.

  2003cited by this paper
• The Abrupt Cessation of Therapeutically Administered Sodium Oxybate (GHB) Does Not Cause Withdrawal Symptoms

  2003cited by this paper
• Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys.

  2003cited by this paper
• A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.

  2003cited by this paper
• Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.

  2003cited by this paper
• Dementia praecox and paraphrenia

  2002cited by this paper
• Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal.

  2002cited by this paper
• Trends in Illicit Drug Emergencies: The Emerging Role of Gamma-Hydroxybutyrate

  2002cited by this paper
• A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.

  2002cited by this paper
• GHB: a new and novel drug of abuse.

  2001cited by this paper
• Gamma-hydroxybutyric acid and alcohol-related syndromes.

  2000cited by this paper
• Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence.

  2000cited by this paper
• Gamma-hydroxybutyrate associated deaths.

  2000cited by this paper
• Abuse and therapeutic potential of gamma-hydroxybutyric acid.

  2000cited by this paper
• Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients.

  2000cited by this paper
• Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys.

  1999cited by this paper
• A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration.

  1999cited by this paper
• Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers

  1999cited by this paper
• Evaluation of the reinforcing and discriminative stimulus effects of γ-hydroxybutyrate in rhesus monkeys

  1999cited by this paper
• Prevalence of drugs used in cases of alleged sexual assault.

  1999cited by this paper
• Clinical Course of γ-Hydroxybutyrate Overdose.

  1998cited by this paper
• Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients.

  1997cited by this paper
• An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group.

  1996cited by this paper
• Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB)

  1996cited by this paper
• Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study.

  1993cited by this paper
• GHB use in South Carolina.

  1992cited by this paper
• Acute poisoning from gamma-hydroxybutyrate in California.

  1992cited by this paper
• Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate.

  1990cited by this paper
• Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.

  1989cited by this paper
• Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.

  1986cited by this paper
• Gamma-hydroxybutyrate in the treatment of schizophrenia.

  1983cited by this paper
• Gamma-Hydroxybutyrate Treatment of Schizophrenia: A Pilot Study

  1981cited by this paper
• Actions and interactions with alcohol of drugs on psychomotor skills: comparison of diazepam and gamma-hydroxybutyric acid.

  1978cited by this paper
• Assessment of coma and impaired consciousness. A practical scale.

  1974cited by this paper
• Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory.

  1971cited by this paper
• CLINICAL APPLICATION OF 4‐HYDROXYBUTYRATE SODIUM AND 4‐BUTYROLACTONE IN NEUROPSYCHIATRIC PATIENTS

  1966cited by this paper

• Novel Psychoactive Drugs

  2019cites this paper
• Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia

  2018cites this paper
• An Algorithmic Approach to the management of Insomnia in Patients with Schizophrenia

  2017cites this paper
• Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs

  2017cites this paper
• Detection of GHB at low levels in non-spiked beverages using solid phase extraction and gas chromatography–mass spectrometry

  2017cites this paper
• The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.

  2016cites this paper
• Positive allosteric modulation of the GHB high-affinity binding site by the GABAA receptor modulator monastrol and the flavonoid catechin.

  2014cites this paper
• Comparative study of equimolar doses of gamma-hydroxybutyrate (GHB), 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL) on catalepsy after acute and chronic administration.

  2013cites this paper
• Rapid analysis of neurotransmitters in rat brain using ultra-fast liquid chromatography and tandem mass spectrometry: application to a comparative study in normal and insomnic rats.

  2013cites this paper
• Sociodemographic and substance use characteristics of γ hydroxybutyrate (GHB) dependent inpatients and associations with dependence severity.

  2013cites this paper
• Reconsidering GHB: orphan drug or new model antidepressant?

  2012cites this paper
• Narcolepsy presenting as schizophrenia: a literature review and two case reports.

  2011cites this paper
• Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome

  2011cites this paper
• Commenting on"a review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia," by Kantrowitzet al.

  2010cites this paper